

Cannabis-based products for medicinal use: assessing the impact

In a [February 2019 commission](#), the Home Secretary asked the ACMD to:

provide an outline for an assessment framework. This should set out how the ACMD will assess the various impacts of rescheduling cannabis-based products for medicinal use to Schedule 2 under the 2001 Regulations, and the data sources (including those provided by the Home Office and DHSC) the ACMD will use by November 2019?

The ACMD are pleased to provide this outline assessment framework, and will use it to provide a full report assessing the impacts of the rescheduling of CBPMs to Schedule 2, by November 2020.